Synthesis of New Potential Lipophilic Co‐Drugs of 2‐Chloro‐2′‐deoxyadenosine (Cladribine, 2‐CdA, Mavenclad®, Leustatin®) and 6‐Azauridine (z 6 U) with Valproic Acid

2‐Chloro‐2′‐deoxyadenosine (cladribine, 1 ) was acylated with valproic acid ( 2 ) under various reaction conditions yielding 2‐chloro‐2′‐deoxy‐3′,5′‐ O ‐divalproyladenosine ( 3 ) as well as the 3′‐ O ‐ and 5′‐ O ‐monovalproylated derivatives, 2‐chloro‐2′‐deoxy‐3′‐ O ‐valproyladenosine ( 4 ) and 2‐chloro‐2′‐deoxy‐5′‐ O ‐valproyladenosine ( 5 ), as new co‐drugs. In addition, 6‐azauridine‐2′,3′‐ O ‐(ethyl levulinate) ( 8 ) was valproylated at the 5′‐OH group (→ 9 ). All products were characterized by 1 H‐ and 13 C‐NMR spectroscopy and ESI mass spectrometry. The structure of the by‐product 6 ( N ‐cyclohexyl‐ N ‐(cyclohexylcarbamoyl)‐2‐propylpentanamide), formed upon valproylation of cladribine in the presence of N , N ‐dimethylaminopyridine and dicyclohexylcarbodiimide, was analyzed by X‐ray crystallography. Cladribine as well as its valproylated co‐drugs were tested upon their cancerostatic/cancerotoxic activity in human astrocytoma/oligodendroglioma GOS‐3 cells, in rat malignant neuro ectodermal BT4Ca cells, as well as in phorbol‐12‐myristate 13‐acetate (PMA)‐differentiated human THP‐1 macrophages. The most important result of these experiments is the finding that only the 3′‐ O ‐valproylated derivative 4 exhibits a significant antitumor activity while the 5′‐ O ‐ as well as the 3′,5′‐ O ‐divalproylated cladribine derivatives 3 and 5 proved to be inactive.